210 related articles for article (PubMed ID: 34310602)
1. The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030.
Vinkeles Melchers NVS; Stolk WA; van Loon W; Pedrique B; Bakker R; Murdoch ME; de Vlas SJ; Coffeng LE
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009604. PubMed ID: 34310602
[TBL] [Abstract][Full Text] [Related]
2. [Onchocerciasis].
Enk CD; Gardlo K; Ruzicka T; BenEzra D
Hautarzt; 2003 Jun; 54(6):513-7. PubMed ID: 12759735
[TBL] [Abstract][Full Text] [Related]
3. How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?
Vinkeles Melchers NVS; Stolk WA; Murdoch ME; Pedrique B; Kloek M; Bakker R; de Vlas SJ; Coffeng LE
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009489. PubMed ID: 34115752
[TBL] [Abstract][Full Text] [Related]
4. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
Turner HC; Walker M; Churcher TS; Basáñez MG
Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
[TBL] [Abstract][Full Text] [Related]
5. Eye lesions, blindness and visual impairment in the Taraba river valley, Nigeria and their relation to onchocercal microfilariae in skin.
Akogun OB
Acta Trop; 1992 Jun; 51(2):143-9. PubMed ID: 1354932
[TBL] [Abstract][Full Text] [Related]
6. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results.
Tekle AH; Zouré HG; Noma M; Boussinesq M; Coffeng LE; Stolk WA; Remme JH
Infect Dis Poverty; 2016 Jun; 5(1):66. PubMed ID: 27349645
[TBL] [Abstract][Full Text] [Related]
7. Progress toward elimination of onchocerciasis in the Americas - 1993-2012.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2013 May; 62(20):405-8. PubMed ID: 23698606
[TBL] [Abstract][Full Text] [Related]
8. Concurrence of dermatological and ophthalmological morbidity in onchocerciasis.
Coffeng LE; Fobi G; Ozoh G; Bissek AC; Nlatté BO; Enyong P; Olinga JM; Zouré HG; Habbema JD; Stolk WA; de Vlas SJ; Boussinesq M; Noma M
Trans R Soc Trop Med Hyg; 2012 Apr; 106(4):243-51. PubMed ID: 22342170
[TBL] [Abstract][Full Text] [Related]
9. African Programme For Onchocerciasis Control 1995-2015: model-estimated health impact and cost.
Coffeng LE; Stolk WA; Zouré HG; Veerman JL; Agblewonu KB; Murdoch ME; Noma M; Fobi G; Richardus JH; Bundy DA; Habbema D; de Vlas SJ; Amazigo UV
PLoS Negl Trop Dis; 2013; 7(1):e2032. PubMed ID: 23383355
[TBL] [Abstract][Full Text] [Related]
10. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
[TBL] [Abstract][Full Text] [Related]
11. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.
Komlan K; Vossberg PS; Gantin RG; Solim T; Korbmacher F; Banla M; Padjoudoum K; Karabou P; Köhler C; Soboslay PT
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006312. PubMed ID: 29494606
[TBL] [Abstract][Full Text] [Related]
12. River Blindness: Mathematical Models for Control and Elimination.
Basáñez MG; Walker M; Turner HC; Coffeng LE; de Vlas SJ; Stolk WA
Adv Parasitol; 2016; 94():247-341. PubMed ID: 27756456
[TBL] [Abstract][Full Text] [Related]
13. Effect of semiannual treatments of ivermectin on the prevalence and intensity of Onchocerca volvulus skin infection, ocular lesions, and infectivity of Simulium ochraceum populations in southern Mexico.
Rodriguez-Perez MA; Rodriguez MH; Margeli-Perez HM; Rivas-Alcala AR
Am J Trop Med Hyg; 1995 May; 52(5):429-34. PubMed ID: 7771609
[TBL] [Abstract][Full Text] [Related]
14. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.
Nicholls RS; Duque S; Olaya LA; López MC; Sánchez SB; Morales AL; Palma GI
Parasit Vectors; 2018 Apr; 11(1):237. PubMed ID: 29642939
[TBL] [Abstract][Full Text] [Related]
15. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic.
Kennedy MH; Bertocchi I; Hopkins AD; Meredith SE
Ann Trop Med Parasitol; 2002 Apr; 96(3):297-307. PubMed ID: 12061976
[TBL] [Abstract][Full Text] [Related]
16. Onchocercal eye disease and the impact of Mectizan treatment.
Abiose A
Ann Trop Med Parasitol; 1998 Apr; 92 Suppl 1():S11-22. PubMed ID: 9861263
[TBL] [Abstract][Full Text] [Related]
17. Evidence for Suppression of Onchocerciasis Transmission in Bioko Island, Equatorial Guinea.
Moya L; Herrador Z; Ta-Tang TH; Rubio JM; Perteguer MJ; Hernandez-González A; García B; Nguema R; Nguema J; Ncogo P; Garate T; Benito A; Sima A; Aparicio P
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004829. PubMed ID: 27448085
[TBL] [Abstract][Full Text] [Related]
18. Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?
Frempong KK; Walker M; Cheke RA; Tetevi EJ; Gyan ET; Owusu EO; Wilson MD; Boakye DA; Taylor MJ; Biritwum NK; Osei-Atweneboana M; Basáñez MG
Clin Infect Dis; 2016 Jun; 62(11):1338-1347. PubMed ID: 27001801
[TBL] [Abstract][Full Text] [Related]
19. Ivermectin for onchocercal eye disease (river blindness).
Ejere HO; Schwartz E; Wormald R; Evans JR
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002219. PubMed ID: 22895928
[TBL] [Abstract][Full Text] [Related]
20. The positive influence the Onchocerciasis Elimination Program for the Americas has had on Africa programs.
Richards FO; Nwoke BEB; Zarroug I; Tukahebwa E; Negussu N; Higazi TB; Oguttu D; Tadesse Z; Miri E; Aziz N; Habomugisha P; Katabarwa M
Infect Dis Poverty; 2019 Jul; 8(1):52. PubMed ID: 31303175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
